日本語View as Markdown

Transdermal hydrogen therapy for psoriasis using cavity-embedded double-conical microneedles.

空洞埋め込み型二重円錐マイクロニードルを用いた乾癬への経皮的水素送達システムの開発

animal study topical application positive

Abstract

Psoriasis is a chronic inflammatory skin condition driven by a self-reinforcing cycle of oxidative stress and immune dysregulation. Conventional topical agents face barriers from limited skin permeability and systemic side-effect risks. In this study, a double-conical microneedle device with embedded cavities was engineered to carry MgH₂ powders and achieve sustained intracutaneous release of molecular hydrogen. In a murine psoriasis model, the system outperformed calcipotriol cream—a standard-of-care topical agent—by substantially reducing oxidative tissue damage, pro-inflammatory cytokine levels, immune cell infiltration, keratinocyte hyperproliferation, and systemic manifestations. Mechanistic analyses clarified how the oxidative stress–inflammation axis perpetuates psoriatic pathology. The findings establish a microneedle-based transdermal platform as a viable strategy for delivering molecular hydrogen to inflammatory skin conditions.

Mechanism

MgH₂ embedded in microneedles releases molecular hydrogen within skin tissue, selectively scavenging reactive oxygen species and interrupting the mutually reinforcing oxidative stress–inflammation cycle, thereby suppressing keratinocyte hyperproliferation and immune cell infiltration.

Bibliographic

Authors
Zhu D, Lim RYD, Poh YL, Li DZ, Raghavan S, Chen P
Journal
J Control Release
Year
2025 (2025-12-10)
PMID
41083007
DOI
10.1016/j.jconrel.2025.114313

Tags

Disease:皮膚疾患 Delivery:局所投与 Mechanism:ヒドロキシルラジカル消去 免疫調節 炎症抑制 酸化ストレス 活性酸素種

Delivery context

Topical applications have localized-effect reports, but systemic hydrogen intake is most efficient via inhalation. Inhalation carries explosion risk (empirical LFL of 10%; high-concentration devices are not recommended).

Safety notes

Topical applications have localized-effect reports, but systemic hydrogen intake is most efficient via inhalation. Inhalation carries explosion risk (empirical LFL of 10%; high-concentration devices are not recommended).

See also:

Other papers on the same disease / condition

Cite as: H2 Papers — PMID 41083007. https://h2-papers.org/en/papers/41083007
Source: PubMed PMID 41083007